Research Reports

The key therapeutic areas that are expected to receive the greatest focus are cardiovascular and metabolic diseases, cancer diagnosis and infectious diseases. Cancer diagnostics attracts huge amounts of attention owing to the inferior ability of conventional methods of diagnosis to detect diseases in their early stages.

The fragmented nature of the healthcare systems in the United Arab Emirates remains despite the implementation of health reforms in the emirates of Abu Dhabi and Dubai. The two major emirates are currently at different stages in the development and implementation of reform with the gap between them in terms of access to healthcare and pharmaceuticals widening, with Abu Dhabi leading the way.

Diagnostic practice is undergoing a quiet revolution, with in-vitro diagnostic (IVD) tests moving out of the centralized hospital laboratory to POCT locations. POC tests are more expensive than lab-based tests, but promise to reduce the overall cost of healthcare while improving the quality of outcomes. They are thus attractive to manufacturers and increasingly in demand.

Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.

Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration.

The gastrointestinal market is mature and genericized. Over 2004-08, most of the market leading drug classes in this therapy area reported negative or low compound annual growth rates (CAGRs). The largest drug class of the therapy area, proton pump inhibitors, which constituted a market share of 53.2%, recorded a CAGR of 4.8%.